Supreme Court Refuses Inter Partes Review
Akorn’s Win On Difluprednate Patent Will Not Be Reopened
Standards of evidence for obviousness used in US inter partes patent reviews will not be reviewed by the US Supreme Court. Nor will the court consider whether the Federal Circuit can confirm inter partes decisions without issuing an opinion.
You may also be interested in...
Acorda has been denied its request for the US Supreme Court to review a ruling that revolved around the ‘blocking-patent’ doctrine, which has led to invalidity rulings on patents protecting several major brands.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.